Caffeine, Serum or Plasma
Also known as: CAFFEINE S
Use
This test is used for therapeutic monitoring of patients receiving caffeine therapy. Caffeine is commonly used in neonatal intensive care units to treat apnea of prematurity. Monitoring serum or plasma levels ensures therapeutic effectiveness while avoiding potential toxicities associated with high concentrations.
Special Instructions
The test is performed using a Quantitative Enzyme Multiplied Immunoassay Technique and is applicable every day (Sun-Sat). It includes a therapeutic range and toxic levels guidelines that must be strictly adhered to for patient safety.
Limitations
The test may not detect all causes of high serum or plasma caffeine levels, such as ingestion of non-therapeutic caffeine sources. Additionally, results may be affected by improper specimen handling, such as delayed separation of cells or incorrect storage temperatures. Citrated plasma and serum separator tubes (SST) are considered unacceptable and might lead to sample rejection.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 3422-3
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.2 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate from cells ASAP or within 6 hours of collection. Transfer 0.5 mL serum or plasma.
Patient Preparation
None
Storage Instructions
Refrigerate after collection.
Causes for Rejection
Citrated Plasma, Serum separator tube (SST)
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 week |
| Refrigerated | 1 week |
| Frozen | 2 months |